Protracted severe COVID-19 pneumonia following rituximab treatment: caution needed

The outcomes of COVID-19 in patients treated with biologic agents are a subject of intense investigation. Recent data indicated that patients under rituximab (RTX) may carry an increased risk of serious disease. We performed an electronic search in Medline and Scopus using the keywords rituximab and...

Descripción completa

Detalles Bibliográficos
Autores principales: Daoussis, Dimitrios, Leonidou, Lydia, Kalogeropoulou, Christina, Paliogianni, Fotini, Tzouvelekis, Argyrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Case Based Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373601/
https://www.ncbi.nlm.nih.gov/pubmed/34409510
http://dx.doi.org/10.1007/s00296-021-04969-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373601/
https://www.ncbi.nlm.nih.gov/pubmed/34409510
http://dx.doi.org/10.1007/s00296-021-04969-2

Ejemplares similares